AL-3789: A novel ophthalmic angiostatic steroid

Research output: Contribution to journalArticlepeer-review

50 Scopus citations


Ocular neovascular diseases are a leading cause of blindness in the world. Research is beginning to unravel the complex mechanisms involved in the pathogenesis of ocular neovascular diseases, but currently there are very few methods for the effective treatment of these blinding disorders. AL-3789 (Alcon Laboratories) is an angiostatic steroid which shows significant activity in inhibiting new blood vessel formation in a wide variety of models of neovascularisation, including neovascularisation in ocular tissues. This angiostatic steroid has broad angiostatic activity and is effective in a number of different animal species and tissues, regardless of the angiogenic stimulus. AL-3783 is devoid of conventional steroid hormone activity and does not appear to have any other pharmacological side-effects at the doses and routes of administration tested. In preclinical safety studies, AL-3789 has no apparent ocular or systemic toxicity when dosed chronically by topical ocular or by systemic administration. It remains to be seen whether these promising results will be confirmed in clinical studies.

Original languageEnglish
Pages (from-to)1867-1877
Number of pages11
JournalExpert Opinion on Investigational Drugs
Issue number12
StatePublished - 1 Jan 1997


  • AL-3789
  • AL-4940
  • Angiostatic steroids
  • Neovascularisation
  • Ocular angiogenesis


Dive into the research topics of 'AL-3789: A novel ophthalmic angiostatic steroid'. Together they form a unique fingerprint.

Cite this